文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

双氢青蒿素-哌喹用于加蓬和莫桑比克HIV孕妇疟疾间歇性预防治疗的安全性和有效性:一项随机双盲安慰剂对照试验

Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Infect Dis · 2024-01-12

在加蓬和莫桑比克五家中心纳入666名HIV孕妇,随机接受双氢青蒿素-哌喹或安慰剂间歇性预防治疗,均每日服用复方新诺明。分娩时外周疟原虫血症干预组1例(<1%)vs对照组0例,无显著差异;临床疟疾发生率干预组1例vs对照组6例(RR 0.12,95%CI 0.03-0.52,p=0.045)。干预安全,未增加不良妊娠结局。

要点

  • 在低疟疾传播背景下,双氢青蒿素-哌喹间歇性预防治疗未降低HIV孕妇分娩时外周疟原虫血症。
  • 干预组临床疟疾发生率低于对照组(1例 vs 6例;RR 0.12,95%CI 0.03-0.52)。
  • 严重不良事件和不良妊娠结局两组无差异,药物相关不良事件以胃肠道紊乱(<4%)和头痛(<2%)常见。

核心结论

  • 在低疟疾传播背景下,HIV孕妇在复方新诺明预防基础上加用双氢青蒿素-哌喹间歇性预防治疗未降低分娩时外周疟原虫血症,但干预安全且与临床疟疾和总体恶性疟原虫感染风险降低相关,应考虑作为保护HIV孕妇免于疟疾的策略。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,在加蓬和莫桑比克五个中心纳入妊娠≤28周、首次产前检查的HIV孕妇666名,按1:1随机分为干预组(332名)和对照组(334名),按国家分层区组随机(区组大小8)。
  • 干预组每次预定产前检查接受双氢青蒿素-哌喹间歇性预防治疗(每日剂量按体重,目标双氢青蒿素4 mg/kg/日[范围2-10 mg/kg/日]、哌喹18 mg/kg/日[范围16-27 mg/kg/日],每日一次连用3天,直接观察服药),对照组接受安慰剂;所有参与者每日服用复方新诺明(固定复方制剂含甲氧苄啶800 mg和磺胺甲噁唑160 mg)。
  • 主要结局为分娩时显微镜检测的外周疟原虫血症,改良意向治疗人群包括所有随机分组且有主要结局数据的女性;试验注册号NCT03671109。

主要发现

  • 分娩时外周疟原虫血症:干预组294名中1例(<1%)vs对照组308名中0例。
  • 妊娠期临床疟疾发生率:干预组1例 vs 对照组6例(RR 0.12,95%CI 0.03-0.52,p=0.045)。
  • 事后分析中,总体疟疾感染复合结局(妊娠期或分娩时任何诊断检测发现):干预组311名中14例(5%)vs 对照组320名中31例(10%)(RR 0.48,95%CI 0.27-0.84,p=0.010)。
  • 严重不良事件和不良妊娠结局(如流产、死产、早产和先天畸形)的频率两组无差异。
  • 最常报告的药物相关不良事件为胃肠道紊乱(报告于不到4%的参与者)和头痛(报告于不到2%的参与者),两组无差异。

关键数值与推荐

  • 双氢青蒿素-哌喹目标剂量:双氢青蒿素4 mg/kg/日(范围2-10 mg/kg/日),哌喹18 mg/kg/日(范围16-27 mg/kg/日),每日一次连用3天。
  • 复方新诺明固定复方制剂含甲氧苄啶800 mg和磺胺甲噁唑160 mg,每日服用。
  • 主要结局:分娩时外周疟原虫血症干预组1/294(<1%)vs对照组0/308。
  • 临床疟疾:干预组1例 vs 对照组6例(RR 0.12,95%CI 0.03-0.52,p=0.045)。
  • 总体疟疾感染复合结局:干预组14/311(5%)vs对照组31/320(10%)(RR 0.48,95%CI 0.27-0.84,p=0.010)。

临床怎么用

  • 作者认为,在低疟疾传播背景下,HIV孕妇在复方新诺明预防基础上加用双氢青蒿素-哌喹间歇性预防治疗应考虑作为保护HIV孕妇免于疟疾的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cornerstone of malaria prevention in pregnancy, intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine, is contraindicated in women with HIV who are receiving co-trimoxazole prophylaxis. We assessed whether IPTp with dihydroartemisinin-piperaquine is safe and effective in reducing the risk of malaria infection in women with HIV receiving co-trimoxazole prophylaxis and antiretroviral drugs. METHODS: For this randomised, double-blind, placebo-controlled clinical trial, women with HIV attending the first antenatal care clinic visit, resident in the study area, and with a gestational age up to 28 weeks were enrolled at five sites in Gabon and Mozambique. Participants were randomly assigned (1:1) to receive either IPTp with dihydroartemisinin-piperaquine at each scheduled antenatal care visit plus daily co-trimoxazole (intervention group) or placebo at each scheduled antenatal care visit plus daily co-trimoxazole (control group). Randomisation was done centrally via block randomisation (block sizes of eight), stratified by country. IPTp was given over 3 days under direct observation by masked study personnel. The number of daily IPTp tablets was based on bodyweight and according to the treatment guidelines set by WHO (target dose of 4 mg/kg per day [range 2-10 mg/kg per day] of dihydroartemisinin and 18 mg/kg per day [range 16-27 mg/kg per day] of piperaquine given once a day for 3 days). At enrolment, all participants received co-trimoxazole (fixed combination drug containing 800 mg trimethoprim and 160 mg sulfamethoxazole) for daily intake. The primary study outcome was prevalence of peripheral parasitaemia detected by microscopy at delivery. The modified intention-to-treat population included all randomly assigned women who had data for the primary outcome. Secondary outcomes included frequency of adverse events, incidence of clinical malaria during pregnancy, and frequency of poor pregnancy outcomes. All study personnel, investigators, outcome assessors, data analysts, and participants were masked to treatment assignment. This study is registered with ClinicalTrials.gov, NCT03671109. FINDINGS: From Sept 18, 2019, to Nov 26, 2021, 666 women (mean age 28·5 years [SD 6·4]) were enrolled and randomly assigned to the intervention (n=332) and control (n=334) groups. 294 women in the intervention group and 308 women in the control group had peripheral blood samples taken at delivery and were included in the primary analysis. Peripheral parasitaemia at delivery was detected in one (<1%) of 294 women in the intervention group and none of 308 women in the control group. The incidence of clinical malaria during pregnancy was lower in the intervention group than in the control group (one episode in the intervention group vs six in the control group; relative risk [RR] 0·12, 95% CI 0·03-0·52, p=0·045). In a post-hoc analysis, the composite outcome of overall malaria infection (detected by any diagnostic test during pregnancy or delivery) was lower in the intervention group than in the control group (14 [5%] of 311 women vs 31 [10%] of 320 women; RR 0·48, 95% CI 0·27-0·84, p=0·010). The frequency of serious adverse events and poor pregnancy outcomes (such as miscarriages, stillbirths, premature births, and congenital malformations) did not differ between groups. The most frequently reported drug-related adverse events were gastrointestinal disorder (reported in less than 4% of participants) and headache (reported in less than 2% of participants), with no differences between study groups. INTERPRETATION: In the context of low malaria transmission, the addition of IPTp with dihydroartemisinin-piperaquine to co-trimoxazole prophylaxis in pregnant women with HIV did not reduce peripheral parasitaemia at delivery. However, the intervention was safe and associated with a decreased risk of clinical malaria and overall Plasmodium falciparum infection, so it should be considered as a strategy to protect pregnant women with HIV from malaria. FUNDING: European and Developing Countries Clinical Trials Partnership 2 (EDCTP2) and Medicines for Malaria Venture. TRANSLATIONS: For the Portuguese and French translations of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. González R, Nhampossa T, Mombo-Ngoma G, et al. Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2024. PMID: 38224706. doi:10.1016/S1473-3099(23)00738-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。